Takeda sets up development center in China

13 February 2012

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO 4502), says it is establishing the Takeda Shanghai Development Center (TSDC) within its wholly-owned Shanghai-based Takeda (China) Holdings, noting that this important step reflects the company’s strategic commitment to Asia and to China in particular.

Takeda is now enhancing its business in China through TCH’s wholly-owned subsidiaries, Takeda Pharmaceutical (China) Company, which is responsible for marketing and sales, and Tianjin Takeda Pharmaceuticals in Tianjin, which is responsible for manufacturing. Together with Takeda China and Tianjin Takeda, TSDC will help to drive Takeda’s ambitious growth agenda in China and in the broader Asian region.

Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center in Singapore (TGRD Asia) and Millennium Pharmaceuticals in Cambridge, USA, wholly-owned subsidiaries of Takeda, through outsourcing to contract research organizations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK